-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are approximately 67,000 new cases of head and neck squamous cell carcinoma (HNSCC) in the United States each year
.
The main risk factors for head and neck squamous cell carcinoma are smoking, alcohol abuse, and human papillomavirus (HPV) infection
Infect
This is a multi-institutional phase 2 clinical trial to determine the overall efficacy of cetuximab plus nivolumab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Survival rate (OS)
.
Patients with recurrent/metastatic head and neck squamous cell carcinoma were recruited and treated with cetuximab (500 mg/m2) + nivolumab (240 mg) for 24 courses
.
The primary endpoint was one-year overall survival (OS)
Overall survival of cohorts A and B
Overall survival of cohorts A and B
A total of 95 patients were recruited, 88 of whom were included in the overall survival analysis and divided into two cohorts based on prior treatment: Cohort A (n=45), previously treated for R/M HNSCC; Cohort B (n=43), who had not received relevant treatment before
.
With a median follow-up of 15.
9 months, the median overall survival in cohort A was 11.
4 months, and the one-year overall survival rate was 50%
The median overall survival in cohort A was 11.
p16 negativity was associated with higher response rates p16 negativity was associated with higher response rates In p16-positive patients, HPV DNA counts were lower than those with higher HPV DNA loads than higher response rates (p= 0.
The combination regimen of cetuximab and nivolumab showed some therapeutic activity in both previously treated and untreated recurrent/metastatic head and neck squamous cell carcinoma, Worth further study
Original source:
Chung Christine H,Li Jiannong,Steuer Conor E et al.
Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma .
[J] .
Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma
